计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor. Target: PDE Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability, reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. Pentoxifylline is also an antagonist at adenosine 2 receptors . Pentoxifylline is generally well tolerated. Based on the totality of the available evidence, it is possible that pentoxifylline could have a place in the treatment of IC as a means of improving walking distance and as a complimentary treatment assuming all other essential measures such as lifestyle change, exercise and treatment for secondary prevention have been taken into account . Pentoxifylline reduce AST and ALT levels and may improve liver histological scores in patients with NALFD/NASH, but did not appear to affect cytokines. Large, prospective, and well-designed randomized, controlled studies are needed to address this issue .Pentoxifylline是竞争性非选择性磷酸二酯酶(PDE)抑制剂
Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor. Target: PDE Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability, reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. Pentoxifylline is also an antagonist at adenosine 2 receptors . Pentoxifylline is generally well tolerated. Based on the totality of the available evidence, it is possible that pentoxifylline could have a place in the treatment of IC as a means of improving walking distance and as a complimentary treatment assuming all other essential measures such as lifestyle change, exercise and treatment for secondary prevention have been taken into account . Pentoxifylline reduce AST and ALT levels and may improve liver histological scores in patients with NALFD/NASH, but did not appear to affect cytokines. Large, prospective, and well-designed randomized, controlled studies are needed to address this issue .
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 咪唑并嘧啶类 |
| 亚类(Subclass) | 嘌呤和嘌呤衍生物 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 黄嘌呤 |
| 其他上位类(Alternative Parents) | 6-氧嘌呤 生物碱及其衍生物 嘧啶酮类 N-取代咪唑 乙烯基酰胺 杂芳族化合物 尿素 内酰胺类 酮类 氮杂环化合物 有机光子化合物 有机氮化合物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 6-羰基嘌呤 - 生物碱或其衍生物 - 芳香族杂多环化合物 - 氮杂环 - 吡唑 - 羰基 - 杂芳香族化合物 - 烃衍生物 - 咪唑 - 酮 - 肟 - N-取代咪唑 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 嘌呤酮 - 嘧啶 - 嘧啶酮 - 脲 - 乙烯酰胺 - 黄酮 |
| 描述(Description) | 该化合物属于黄嘌呤类有机化合物。这类嘌呤衍生物在嘌呤骨架的2位和6位碳原子上共轭连接酮基团。 |
| 外部描述符(External Descriptors) | oxopurine |
| ALogP | 0.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
H302: 吞食有害
P264: 处理后要彻底洗手。
P270: 使用本产品时,请勿进食、饮水或吸烟。
P330: 漱口
P301+P312: 如误吞咽:如感觉不适,呼叫急救中心/医生。
P501: 将内容物/容器处理到。。。